BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34714913)

  • 1. BCL11A promotes myeloid leukemogenesis by repressing PU.1 target genes.
    Sunami Y; Yokoyama T; Yoshino S; Takahara T; Yamazaki Y; Harada H; Nakamura T
    Blood Adv; 2022 Mar; 6(6):1827-1843. PubMed ID: 34714913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trib1 promotes acute myeloid leukemia progression by modulating the transcriptional programs of Hoxa9.
    Yoshino S; Yokoyama T; Sunami Y; Takahara T; Nakamura A; Yamazaki Y; Tsutsumi S; Aburatani H; Nakamura T
    Blood; 2021 Jan; 137(1):75-88. PubMed ID: 32730594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CLEC5A (MDL-1) is a novel PU.1 transcriptional target during myeloid differentiation.
    Batliner J; Mancarelli MM; Jenal M; Reddy VA; Fey MF; Torbett BE; Tschan MP
    Mol Immunol; 2011 Jan; 48(4):714-9. PubMed ID: 21094529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A.
    Xu J; Bauer DE; Kerenyi MA; Vo TD; Hou S; Hsu YJ; Yao H; Trowbridge JJ; Mandel G; Orkin SH
    Proc Natl Acad Sci U S A; 2013 Apr; 110(16):6518-23. PubMed ID: 23576758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of Notch-1 expression decreases PU.1-mediated myeloid differentiation signaling in acute myeloid leukemia.
    Chen PM; Yen CC; Wang WS; Lin YJ; Chu CJ; Chiou TJ; Liu JH; Yang MH
    Int J Oncol; 2008 Jun; 32(6):1335-41. PubMed ID: 18497996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-operative leukemogenesis in acute myeloid leukemia and acute promyelocytic leukemia reveals C/EBPα as a common target of TRIB1 and PML/RARA.
    Keeshan K; Vieugué P; Chaudhury S; Rishi L; Gaillard C; Liang L; Garcia E; Nakamura T; Omidvar N; Kogan SC
    Haematologica; 2016 Oct; 101(10):1228-1236. PubMed ID: 27390356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML.
    Barth J; Abou-El-Ardat K; Dalic D; Kurrle N; Maier AM; Mohr S; Schütte J; Vassen L; Greve G; Schulz-Fincke J; Schmitt M; Tosic M; Metzger E; Bug G; Khandanpour C; Wagner SA; Lübbert M; Jung M; Serve H; Schüle R; Berg T
    Leukemia; 2019 Jun; 33(6):1411-1426. PubMed ID: 30679800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FBW7 Inhibits Myeloid Differentiation in Acute Myeloid Leukemia via GSK3-Dependent Ubiquitination of PU.1.
    Mishra M; Thacker G; Sharma A; Singh AK; Upadhyay V; Sanyal S; Verma SP; Tripathi AK; Bhatt MLB; Trivedi AK
    Mol Cancer Res; 2021 Feb; 19(2):261-273. PubMed ID: 33188146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines.
    Murray-Stewart T; Woster PM; Casero RA
    Amino Acids; 2014 Mar; 46(3):585-94. PubMed ID: 23508577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene.
    Yin B; Delwel R; Valk PJ; Wallace MR; Loh ML; Shannon KM; Largaespada DA
    Blood; 2009 Jan; 113(5):1075-85. PubMed ID: 18948576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
    Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
    J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High BCL11A Expression in Adult Acute Myeloid Leukemia Patients Predicts a Worse Clinical Outcome.
    Dong H; Shi P; Zhou Y; Yu Y; Guo X; Yao Y; Liu P; Xu B
    Clin Lab; 2017 Jan; 63(1):85-90. PubMed ID: 28164500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Runx1 regulation of Pu.1 corepressor/coactivator exchange identifies specific molecular targets for leukemia differentiation therapy.
    Gu X; Hu Z; Ebrahem Q; Crabb JS; Mahfouz RZ; Radivoyevitch T; Crabb JW; Saunthararajah Y
    J Biol Chem; 2014 May; 289(21):14881-95. PubMed ID: 24695740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCL11A expression in acute myeloid leukemia.
    Tao H; Ma X; Su G; Yin J; Xie X; Hu C; Chen Z; Tan D; Xu Z; Zheng Y; Liu H; He C; Mao ZJ; Yin H; Wang Z; Chang W; Gale RP; Chen Z; Wu D; Yin B
    Leuk Res; 2016 Feb; 41():71-5. PubMed ID: 26707798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COP1 targets C/EBPα for degradation and induces acute myeloid leukemia via Trib1.
    Yoshida A; Kato JY; Nakamae I; Yoneda-Kato N
    Blood; 2013 Sep; 122(10):1750-60. PubMed ID: 23884858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inverse and correlative relationships between TRIBBLES genes indicate non-redundant functions during normal and malignant hemopoiesis.
    Salomé M; Hopcroft L; Keeshan K
    Exp Hematol; 2018 Oct; 66():63-78.e13. PubMed ID: 30031847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML.
    Cusan M; Cai SF; Mohammad HP; Krivtsov A; Chramiec A; Loizou E; Witkin MD; Smitheman KN; Tenen DG; Ye M; Will B; Steidl U; Kruger RG; Levine RL; Rienhoff HY; Koche RP; Armstrong SA
    Blood; 2018 Apr; 131(15):1730-1742. PubMed ID: 29453291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCL11A and MDR1 expressions have prognostic impact in patients with acute myeloid leukemia treated with chemotherapy.
    Xutao G; PengCheng S; Yin L; Huijuan D; Yan W; Haiqing Z; Bing X
    Pharmacogenomics; 2018 Mar; 19(4):343-348. PubMed ID: 29469608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.
    Fiskus W; Sharma S; Shah B; Portier BP; Devaraj SG; Liu K; Iyer SP; Bearss D; Bhalla KN
    Leukemia; 2014 Nov; 28(11):2155-64. PubMed ID: 24699304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.
    Vangala RK; Heiss-Neumann MS; Rangatia JS; Singh SM; Schoch C; Tenen DG; Hiddemann W; Behre G
    Blood; 2003 Jan; 101(1):270-7. PubMed ID: 12393465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.